HK1072559A1 - Methods and dosage forms for controled delivery ofpaliperidone - Google Patents

Methods and dosage forms for controled delivery ofpaliperidone

Info

Publication number
HK1072559A1
HK1072559A1 HK05105362A HK05105362A HK1072559A1 HK 1072559 A1 HK1072559 A1 HK 1072559A1 HK 05105362 A HK05105362 A HK 05105362A HK 05105362 A HK05105362 A HK 05105362A HK 1072559 A1 HK1072559 A1 HK 1072559A1
Authority
HK
Hong Kong
Prior art keywords
ofpaliperidone
controled
delivery
methods
dosage forms
Prior art date
Application number
HK05105362A
Other languages
English (en)
Inventor
Yam Noymi
Reyes Iran
Davar Nipun
Ayer Atul
Lee Julie
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1072559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of HK1072559A1 publication Critical patent/HK1072559A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK05105362A 2002-07-29 2005-06-28 Methods and dosage forms for controled delivery ofpaliperidone HK1072559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26
PCT/US2003/023433 WO2004010981A1 (en) 2002-07-29 2003-07-28 Methods and dosage forms for controlled delivery of paliperidone

Publications (1)

Publication Number Publication Date
HK1072559A1 true HK1072559A1 (en) 2005-09-02

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05105362A HK1072559A1 (en) 2002-07-29 2005-06-28 Methods and dosage forms for controled delivery ofpaliperidone

Country Status (29)

Country Link
US (1) US20040092534A1 (ja)
EP (1) EP1539115B1 (ja)
JP (1) JP4500679B2 (ja)
KR (1) KR100699516B1 (ja)
CN (1) CN1684670A (ja)
AR (1) AR040721A1 (ja)
AT (1) ATE373472T1 (ja)
AU (1) AU2003256844A1 (ja)
BR (1) BR0313139A (ja)
CA (1) CA2494234C (ja)
CO (1) CO5580742A2 (ja)
CY (1) CY1107096T1 (ja)
DE (1) DE60316454T2 (ja)
DK (1) DK1539115T3 (ja)
ES (1) ES2293039T3 (ja)
HK (1) HK1072559A1 (ja)
HR (1) HRP20050077B1 (ja)
IL (1) IL166489A (ja)
MX (1) MXPA05001191A (ja)
MY (1) MY137049A (ja)
NO (1) NO324821B1 (ja)
NZ (1) NZ570198A (ja)
PE (1) PE20040132A1 (ja)
PL (1) PL210119B1 (ja)
PT (1) PT1539115E (ja)
RU (1) RU2321391C2 (ja)
TW (1) TWI363637B (ja)
WO (1) WO2004010981A1 (ja)
ZA (1) ZA200501641B (ja)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
EP1802286B1 (en) * 2004-08-04 2008-07-23 ALZA Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
EP1912622A2 (en) * 2005-08-04 2008-04-23 Alza Corporation Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
WO2007081736A1 (en) * 2006-01-06 2007-07-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
JP5869745B2 (ja) 2006-02-03 2016-02-24 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療
US20070232624A1 (en) 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
EP3659608A1 (en) 2006-06-21 2020-06-03 Opko Ireland Global Holdings, Ltd. Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
ES2956794T3 (es) 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
ATE530170T1 (de) * 2007-08-21 2011-11-15 Teva Pharma Paliperidonformulierung mit verzögerter freisetzung
WO2009042803A1 (en) 2007-09-25 2009-04-02 Teva Pharmaceutical Industries Ltd. Imatinib compositions
US9439906B2 (en) * 2007-12-19 2016-09-13 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
EP2280967A2 (en) * 2008-03-27 2011-02-09 Actavis Group PTC EHF Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity
EP2326312A1 (en) * 2008-07-25 2011-06-01 KRKA, D.D., Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
WO2010044097A2 (en) 2008-09-15 2010-04-22 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
RU2510266C2 (ru) * 2008-09-30 2014-03-27 Эндо Фармасьютикалз Солюшнз Инк. Имплантируемое устройство для доставки рисперидона и способы его применения
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
EP2488162A2 (en) * 2009-10-16 2012-08-22 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
WO2011114213A1 (en) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
KR102125424B1 (ko) 2010-03-29 2020-06-22 사이토크로마 인코포레이티드 부갑상선 수준을 낮추기 위한 방법 및 조성물
RU2591194C2 (ru) * 2010-04-22 2016-07-10 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2012014052A2 (en) 2010-07-30 2012-02-02 Micro Labs Limited Novel coated extended release pharmaceutical compositions containing paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
ES2846823T3 (es) 2013-03-15 2021-07-29 Intra Cellular Therapies Inc Compuestos orgánicos
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
AU2014360452C1 (en) 2013-12-03 2019-05-16 Intra-Cellular Therapies, Inc. Novel methods
BR112016023162B1 (pt) 2014-04-04 2022-11-29 Intra-Cellular Therapies, Inc Compostos orgânicos gama-carbolinas, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento ou na profilaxia de transtornos de sistema nervoso central
CN106456638A (zh) 2014-04-04 2017-02-22 细胞内治疗公司 有机化合物
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
SG10201911274TA (en) 2014-08-07 2020-02-27 Opko Ireland Global Holdings Ltd Adjunctive therapy with 25-hydroxyvitamin d
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
PL3838274T3 (pl) 2016-01-26 2024-04-02 Intra-Cellular Therapies, Inc. Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN
EP3888656A1 (en) 2016-03-25 2021-10-06 Intra-Cellular Therapies, Inc. Deuterated heterocyclic gamma-carboline compounds and their use in the treatment or prophylaxis of a central nervous system disorder
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
BR112018069727A2 (pt) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd métodos de tratamento com vitamina d
WO2017174096A1 (en) 2016-04-05 2017-10-12 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
CN110072518B (zh) 2016-10-12 2021-10-26 细胞内治疗公司 无定形固体分散体
EP3544593A4 (en) * 2016-11-23 2020-11-25 Children's Hospital Medical Center PALIPERIDONE FOR THE TREATMENT OF DRUG REFRACTORY IRRITABILITY AND AUTISTIC SPECTRUM DISORDER
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
JP6987868B2 (ja) 2016-12-29 2022-01-05 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
MX2019011329A (es) 2017-03-24 2019-12-02 Intra Celular Therapies Inc Composiciones novedosas y metodos.
AU2018307479B2 (en) 2017-07-26 2024-06-20 Intra-Cellular Therapies, Inc. Organic compounds
IL272252B2 (en) 2017-07-26 2024-03-01 Intra Cellular Therapies Inc Transformed histories of gamma-carbolines fused with heterocyclics, pharmaceutical preparations containing them and their use for treatment
US20210009592A1 (en) 2018-03-23 2021-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP7462568B2 (ja) 2018-03-23 2024-04-05 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
AU2019328528A1 (en) 2018-08-31 2021-03-18 Intra-Cellular Therapies, Inc. Novel methods
KR20220029744A (ko) 2019-07-07 2022-03-08 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규 방법
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
WO2023220251A2 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of an antipsychotic
WO2024145659A1 (en) 2022-12-30 2024-07-04 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
SI1033128T2 (sl) * 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
ATE234602T1 (de) * 1996-08-16 2003-04-15 Alza Corp Verabreichungsform zur abgabe von steigenden wirkstoffdosen
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP1083879B1 (en) * 1998-06-03 2004-09-29 Alza Corporation Devices for providing prolonged drug therapy
ATE323493T1 (de) * 1998-11-02 2006-05-15 Alza Corp Gesteuerte freisetzung von antidepressiva
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
CN1161101C (zh) * 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
EP1611881A1 (en) * 1999-03-31 2006-01-04 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
US20040092534A1 (en) 2004-05-13
IL166489A0 (en) 2006-01-15
PE20040132A1 (es) 2004-03-06
EP1539115A1 (en) 2005-06-15
DE60316454T2 (de) 2008-06-26
JP4500679B2 (ja) 2010-07-14
TWI363637B (en) 2012-05-11
KR20050044895A (ko) 2005-05-13
MXPA05001191A (es) 2005-09-12
NZ570198A (en) 2010-01-29
CO5580742A2 (es) 2005-11-30
KR100699516B1 (ko) 2007-03-26
DE60316454D1 (de) 2007-10-31
DK1539115T3 (da) 2008-01-28
PL210119B1 (pl) 2011-12-30
RU2005102105A (ru) 2005-08-10
PT1539115E (pt) 2008-01-14
ATE373472T1 (de) 2007-10-15
NO324821B1 (no) 2007-12-10
NO20050956L (no) 2005-04-27
EP1539115B1 (en) 2007-09-19
ES2293039T3 (es) 2008-03-16
IL166489A (en) 2014-01-30
RU2321391C2 (ru) 2008-04-10
AU2003256844A1 (en) 2004-02-16
AR040721A1 (es) 2005-04-20
CA2494234C (en) 2009-10-27
WO2004010981A1 (en) 2004-02-05
CN1684670A (zh) 2005-10-19
MY137049A (en) 2008-12-31
HRP20050077A2 (en) 2005-12-31
JP2005535682A (ja) 2005-11-24
CA2494234A1 (en) 2004-02-05
BR0313139A (pt) 2005-07-05
CY1107096T1 (el) 2012-10-24
HRP20050077B1 (hr) 2013-11-22
PL376258A1 (en) 2005-12-27
ZA200501641B (en) 2005-08-31
TW200418524A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
HK1072559A1 (en) Methods and dosage forms for controled delivery ofpaliperidone
HK1254943A1 (zh) 治療藥物遞送裝置和方法
AU2003266133A8 (en) Materials and methods for drug delivery and uptake
AU2003299849A8 (en) Drug delivery apparatus
EP1638639A4 (en) DRUG DELIVERY METHOD AND METHOD
GB0307082D0 (en) Drug delivery device and method
HK1087008A1 (en) An allergen dosage form
EP1539129A4 (en) DOSAGE FORMS AND RELEVANT THERAPIES
EP1477119A4 (en) METHOD OF DRUG DELIVERY
EP1478345A4 (en) NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS
GB0215904D0 (en) Drug delivery system and method
EP1648327A4 (en) ORAL DEVICES AND METHODS OF CONTROLLED MEDICAMENT DELIVERY
ZA200506240B (en) Coated particles and pharmaceutical dosage forms
EP1665179A4 (en) METHOD AND APPARATUS FOR DISTRIBUTING DRUGS
HK1072558A1 (en) Methods and dosage forms for controlled delivery of oxycodone
AU2003265226A8 (en) Transdermal drug delivery device, method and use
EP1708780A4 (en) DISTRIBUTION DEVICE AND DISTRIBUTION METHOD
GB0301934D0 (en) Delivery apparatus and location method
PL377791A1 (pl) Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
GB2385273B (en) Drug delivery device
HK1057737A1 (en) Component arranging and delivering apparatus
EP1549380A4 (en) SYSTEM AND METHOD FOR ADMINISTERING DRUGS
SG116507A1 (en) Pharmaceutical dosage form and method of making.
SG118196A1 (en) Content delivery system and content delivery apparatus
GB0223098D0 (en) Medicinal apparatus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150728